The Change Initiative Prevention Programme, delivered in partnership with leading global actors, aims to reframe prevention ...

Ultimately the plan will be judged by its real-world impact on health outcomes. At this years’ OHE Annual Lecture in September, Professor Anita Charlesworth will offer reflections on the economic ...

In this blog we (1) summarise the current status of the EQ-5D-5L value set for England; (2) highlight NICE’s recent statement on the values to be used in the reference case; (3) briefly explain why ...

In England, an estimated 378,427 people receive palliative care each year in a range of specialised and generalised services. Overall, the quality of palliative care in England and the wider UK is ...

Digital Health Technologies are a major trend in health care, and successfully adding them to the wider portfolio of health technologies requires coordinated involvement from various stakeholders.

In this report, we highlight the significance of prevention as a cost-effective and often cost-saving investment for public sector resources. Prevention, covering primary, secondary, and tertiary ...

The value of antibiotics often extends beyond what HTA captures. The STEDI framework aims to capture that broader value and our report outlines a roadmap to realising its full potential.

New antibiotics are urgently needed, but their development is hindered by market failure. A ‘volume-delinked model’ subscription approach has been suggested to overcome this market failure, providing ...

In this Insights series, Around the World in HTAs, we shed light on HTA around the world. In this edition, Prof Hasan Huseyin Yildirim, Dilek Sernur Eminoğulları, Dr Tuba Saygın Avşar, and Patricia ...

Our literature review suggests that there are more than 100 inequalities impacting on people living with dementia and their carers across multiple characteristics, circumstances, and in various parts ...

In this report, we describe the design of a globally aligned, value-based, fully-delinked pull incentive, where payers provide manufacturers with a pre-specified subscription fee based on the value of ...

In this report, commissioned and funded by Pfizer, we explore the extent to which previous OHE recommendations for the health technology assessment (HTA) of gene therapies are being achieved in nine ...